Despite predictions that consumers in recessionary times would flock to cheaper over-the-counter drugs, the world's over-the-counter drug market grew just 3.5% in the past three years, according a report released by Kalorama Information.
The Food and Drug Administration should apply consistent regulatory standards across all biologics, Sandoz plans to state Friday in testimony at an FDA public hearing on draft guidances related to the development of biosimilars.
The National Association of Chain Drug Stores expressed its support for the legislative package that will serve as a starting point for the reauthorization of the Prescription Drug User Fee Act in a letter to the bipartisan leadership of the Senate Committee on Health, Education, Labor and Pensions.
People ages 65 years and older reduced their volume of prescriptions, while those ages 19 to 25 years increased their use of prescription drugs as the healthcare-reform law allowed them to remain on their parents' insurance, according to a new report by IMS Health.
Even as Justice Antonin Scalia suggested that mandating all Americans buy healthcare insurance was akin to Big Government saying to Joe Consumer, "Hey, eat your broccoli," one underlying theme became apparent: Health care isn't cheap and won't be getting any cheaper — unless everybody does in fact eat their broccoli.
The U.S. over-the-counter drug market saw strong growth in 2011, thanks to switches of prescription drugs to OTC, gains in the allergy relief products category and holistic marketing, according to a new report from Kline.
A few weeks ago, we joined some 37,000 of our closest friends for the Healthcare Information and Management Systems Society (HIMSS) annual conference. HIMSS is a cause-based, not-for-profit organization focused on providing global leadership for the optimal use of information technology (IT) and management systems for the betterment of health care.
The Food and Drug Administration's director of the Center for Drug Evaluation and Research, Janet Woodcock, on Thursday identified three tools the agency wanted to use in potentially increasing access to appropriate medicines in her opening remarks at the FDA Rx-to-OTC Switch Hearing.
One of the long-term goals of many drug companies has been to win Food and Drug Administration approval for cholesterol-lowering statins as over-the-counter drugs. But it's a goal that has long eluded them due to the agency's concerns about patient safety.
The National Association of Chain Drug Stores on Friday applauded the Senate for passage of the Counterfeit Drug Penalty Enhancement Act (S. 1886), which NACDS said would protect the health and safety of consumers by increasing penalties on criminals that engage in the harmful practice of trafficking in counterfeit medications.
Written testimony submitted by the National Association of Chain Drug Stores underscored chain pharmacies’ commitment to patient safety as part of the next Prescription Drug User Fee Act reauthorization, and emphasized that community pharmacist-provided services help improve health outcomes without the introduction of unproven technologies.
The National Association of Chain Drug Stores on Thursday testified before the House of Representatives' Energy and Commerce Subcommittee on Commerce, Manufacturing and Trade to emphasize retail pharmacy’s commitment to preserving patient safety and high-quality care.
Prescription-only pseudoephedrine regulation has no impact on the methamphetamine trade, according to a Cascade Policy Institute study on the 2005 Oregon law, which restricts access to medicines containing pseudoephedrine.
According to a report prepared last month by the Economic Impact Group discerning the impact prescription-only pseudoephedrine would have on Oklahoma citizens, prescription-only PSE would result in almost 300,000 additional doctor's office visits at an estimated cost reaching $60 million; $6 million would be directly borne by consumers.
Regulators, healthcare providers and the public at large have taken note of the rise in prescription drug substance abuse. A recent article titled "Oxycodone Prescriptions Rose Sharply" in the New York Times (1/11/2012) describes trends of double-digit percentage increases in the dispensing of certain narcotic based painkillers. And many states have, or will be, implementing prescription drug monitoring programs — also known as prescription monitoring programs — that track the physicians prescribing and the patients receiving controlled substances.
While the financial burden that families face due to prescription drugs has declined, costs nevertheless remain a challenge for many of them, according to a new study by nonprofit research organization Rand Corp.
Drug maker Sandoz has started two late-stage clinical trials of biosimilar drugs for treating cancer patients undergoing chemotherapy, the company said Thursday, saying the studies were meant to support the drugs' eventual marketing in the United States.
Approximately 5.3% of high school seniors abused over-the-counter cough-cold medicines in the past month, according to the latest "Monitoring the Future" survey released Wednesday by the National Institute on Drug Abuse.